Company intelligence / Profile preview
Chemokine Therapeutics Corp.
Vancouver, British Columbia, Canadachemokine.net ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Chemokine Therapeutics was a product-focused biotechnology company developing peptide-based drugs targeting chemokines and their receptors for cancer, blood disorders, and vascular diseases. Lead clinical candidates included CTCE‑9908 for cancer and CTCE‑0214 for neutropenia/stem cell mobilization. Clinical trials showed safety/tolerability in early phases but the company ceased operations after financial difficulties in 2008; no active development is reported since then.[5][9]
- Therapeutic areas
- OncologyCardiovascularNeurologyHematology
- Modalities
- Peptide-based drugs[1]Small molecules (inferred from chemokine/CXCR4 modulator focus)[4]
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Beyond the preview
Go deeper on Chemokine Therapeutics Corp..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Chemokine Therapeutics Corp..